Recombinant vectors as influenza vaccines

Sarah A. Kopecky-Bromberg, Peter Palese

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

17 Scopus citations


The antiquated system used to manufacture the currently licensed inactivated influenza virus vaccines would not be adequate during an influenza virus pandemic. There is currently a search for vaccines that can be developed faster and provide superior, long-lasting immunity to influenza virus as well as other highly pathogenic viruses and bacteria. Recombinant vectors provide a safe and effective method to elicit a strong immune response to a foreign protein or epitope. This review explores the advantages and limitations of several different vectors that are currently being tested, and highlights some of the newer viruses being used as recombinant vectors.

Original languageEnglish
Title of host publicationVaccines for Pandemic Influenza
PublisherSpringer Verlag
Number of pages25
ISBN (Print)9783540921646
StatePublished - 2009

Publication series

NameCurrent Topics in Microbiology and Immunology
ISSN (Print)0070-217X


Dive into the research topics of 'Recombinant vectors as influenza vaccines'. Together they form a unique fingerprint.

Cite this